Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar

Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL cholesterol–lowering treatment. Data from over 25 cardiovascular...

Полное описание

Библиографические подробности
Главные авторы:	Preiss, D, Tobert, JA, Hovingh, GK, Reith, C
Формат:	Journal article
Язык:	English
Опубликовано:	Elsevier 2020

Схожие документы

Lipid-modifying agents, from statins to PCSK9 inhibitors
по: Preiss, D, и др.
Опубликовано: (2020)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
по: Sanjiv Gupta
Опубликовано: (2015-09-01)

United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6/8
по: Caleyachetty, R, и др.
Опубликовано: (2021)

PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance
по: K. O. Shnaider, и др.
Опубликовано: (2023-12-01)

Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
по: Konstantinos Koskinas, и др.
Опубликовано: (2016-07-01)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
по: Christopher LaFratte, и др.
Опубликовано: (2023-09-01)

Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial
по: Nissen, SE, и др.
Опубликовано: (2016)

COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH PCSK9 INHIBITORS VS. STATIN INTOLERANCE
по: Mohsin Haseeb, и др.
Опубликовано: (2023-03-01)

JACC: Asia
по: Jian'an Wang, MD, PhD
Опубликовано: (2021-06-01)

JACC: Asia
по: Valentin Fuster, MD, PhD, и др.
Опубликовано: (2021-06-01)

The PCSK9 decade
по: Gilles Lambert, и др.
Опубликовано: (2012-12-01)

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
по: Mbikay Majambu, и др.
Опубликовано: (2008-06-01)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
по: Shuai Wang, и др.
Опубликовано: (2022-10-01)

PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?
по: Ying Xiao, и др.
Опубликовано: (2022-11-01)

PCSK9 inhibitors
по: Baris Gencer, и др.
Опубликовано: (2015-04-01)

JACC: Case Reports
по: Julia Grapsa, MD, PhD, и др.
Опубликовано: (2019-08-01)

JACC: Case Reports
по: Julia Grapsa, MD, PhD, и др.
Опубликовано: (2020-06-01)

JACC: Case Reports
по: Purvi Parwani, MBBS, MPH, и др.
Опубликовано: (2020-09-01)

Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
по: Preiss, D, и др.
Опубликовано: (2016)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
по: Maram H. Abduljabbar
Опубликовано: (2024-11-01)

Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment
по: Sliz, E, и др.
Опубликовано: (2018)

Vision for JACC: Case Reports
по: Julia Grapsa, MD, PhD
Опубликовано: (2019-06-01)

Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week
по: Armitage, J, и др.
Опубликовано: (2019)

PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
по: A. V. Blokhina, и др.
Опубликовано: (2022-01-01)

Lipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough
по: Markus Mohaupt
Опубликовано: (2016-07-01)

PCSK9 Inhibitors: The Evolving Future
по: Bijay Mukesh Jeswani, и др.
Опубликовано: (2024-11-01)

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
по: Naoto Kuyama, и др.
Опубликовано: (2021-06-01)

Introducing JACC: Basic to Translational Science
по: Douglas L. Mann, MD, и др.
Опубликовано: (2016-01-01)

Case report: Intensive statin and PCSK-9 inhibitor combo reduces plaque volume and stenosis in ischemic stroke patient
по: Weiqi Zeng, и др.
Опубликовано: (2023-08-01)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
по: Preiss, D, и др.
Опубликовано: (2016)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
по: Dennis T. Ko, и др.
Опубликовано: (2018-11-01)

Role of PCSK9 inhibitors in the management of dyslipidaemia
по: Tiny Nair
Опубликовано: (2024-03-01)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
по: Martin Jozef Péč, и др.
Опубликовано: (2023-08-01)

A Comprehensive Review of PCSK9 Inhibitors
по: Caroline Coppinger BS, и др.
Опубликовано: (2022-05-01)

Cholesterol and stroke: role of PCSK9 inhibitors
по: L. Castilla-Guerra, и др.
Опубликовано: (2019-04-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
по: A. Yu. Filatova, и др.
Опубликовано: (2019-06-01)

Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
по: Marianna Puccini, и др.
Опубликовано: (2022-03-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
по: Blom DJ, и др.
Опубликовано: (2016-05-01)

Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: A Systematic Review and Meta-Analysis
по: Zinan ZHAO, и др.
Опубликовано: (2020-10-01)

The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy
по: Lillian Smith, и др.
Опубликовано: (2016-03-01)